drugset / Trial / NCT03309592
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.
Timeline
- Start
- 2017-10-12
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 10 mg | Oral |
| Subject | Tadalafil | Small molecule | 40 mg | Oral |